Abstract
Camptocormia is defined as a marked dystonic flexion of the trunk in the sagittal plane. Camptocormia responds poorly to botulinum toxin injections, manipulation with dopaminergic treatment, and deep brain stimulation. We designed a prospective pilot study to assess the effect of apomorphine infusions on camptocormia. Five patients were enrolled. All five patients responded well to this treatment. The fact that camptocormia responds so well to apomorphine may be explained by the sustained stimulation of the ventrolateral striatal D1 receptors, alleviating this type of dystonia.
References
Ashour R, Jankovic J (2006) Joint and skeletal deformities in Parkinson’s disease, multiple system atrophy, and progressive supranuclear palsy. Mov Disord 21:1856–1863
Asmus F, Gasser T (2010) Dystonia-plus syndromes. Eur J Neurol 17:37–45
Bloch F, Houeto JL, Tezenas du Montel S, Bonnevile F, Etchepare F, Welter ML (2006) Parkinson’s disease with camptocormia. J Neurol Neurosurg Psychiatry 77:1223–1228
Bonnani L, Thomas A, Varanese S, Scorrano V, Onofrj M (2007) Botulinum toxin treatment of lateral axial dystonia in parkinsonism. Mov Disord 22:2097–2103
Bouzgarou E, Dupeyron A, Castelnovo G, Boudousq V, Collombier L, Labauge P, Pelisier J (2007) Camptocormia disclosing Parkinson’s disease. Ann Readapt Med Phys 50:55–59
Brousolle E, Krack P, Thobois S, Xie-Brustolin J, Pollak P (2007) Contribution of Jules Froment to the study of parkinsonian rigidity. Mov Disord 22:909–914
Colzi A, Turner K, Lees A (1998) Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson’s disease. J Neurol Neurosurg Psychiatry 64:573–576
Djaldetti R, Mosberg-Galili R, Sroka H, Merims D, Melamed E (1999) Camptocormia (bent spine) in patients with Parkinson’s disease—characterization and possible pathogenesis of an unusual phenomenon. Mov Disord 14:443–447
Furusawa Y, Mukai Y, Kawazoe T, Sano T, Nakamura H, Sakamoto C, Iwata Y, Wakita M, Nakata Y, Kamiya K, Kobayashi Y, Sakamoto T, Takiyama Y, Murata M (2013) Long-term effect of repeated lidocaine injections into the external oblique for upper camptocormia in Parkinson’s disease. Parkinsonism Relat Disord 19:350–354
Gerton BK, Theeler B, Samii A (2010) Backpack treatment for camptocormia. Mov Disord 25:247–248
Ichinose H, Ikemoto K, Nomura T, Kondo K (2010) Advanced research on dopamine signaling to develop drugs for the treatment of mental disorders: regulation of dopaminergic neural transmission by tyrosine hydroxylase protein at nerve terminals. J Pharmacol Sci 114:17–24
Kanovsky P, Kubova D, Bares M, Hortova H, Streitova H, Rektor I, Znojil V (2002) Levodopa-induced dyskinesias and continuous subcutaneous infusions of apomorphine: results of a two-year, prospective follow-up. Mov Disord 17:188–191
Katzenschlager R, Hughes A, Evans A, Manson A, Hoffman M, Swinn L, Watt H, Bhatia K, Quinn N, Lees A (2005) Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson’s disease: a prospective study using single-dose challenges. Mov Disord 20:151–157
Manson A, Turner K, Lees AJ (2002) Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson’s disease: long-term follow-up study of 64 patients. Mov Disord 17:1235–1241
Margraf NG, Wrede A, Rohr A, Schulz-Schaeffer WJ, Raethjen J, Eymess A, Volkmann J, Mehdorn MH, Jansen O, Deuschl G (2010) Camptocormia in idiopathic Parkinson’s disease: a focal myopathy of the paravertebral muscles. Mov Disord 25:542–551
Marianna C, Chiara S, Luca F, Giovanna C, Matteo F, Chiara O, Renzi R, Leandro P, Gabriella CM (2014) Postural rehabilitation and Kinesio Taping for axial postural disorders in Parkinson’s disease. Arch Phys Med Rehabil. doi:10.1016/j.apmr.2014.01.020
Oeda T, Umemura A, Tomita S, Hayashi R, Kohsaka M, Sawada H (2013) Clinical factors associated with abnormal postures in Parkinson’s disease. PLoS ONE 8(9):73547
Oravivattanakul S, Abboud H, Fernandez H, Itin I (2014) Unusual case of levodopa-responsive camptocormia in a patient with negative dopamine transporter scan and normal DYT 5 gene. Clin Neuropharmacol 37:63–64
Pietz K, Hagell P, Odin P (1998) Subcutaneous apomorphine in late stage Parkinson’s disease: a long term follow up. J Neurol Neurosurg Psychiatry 65:709–716
Reese R, Knudsen K, Falk D, Mehdorn HM, Deuschl G, Volkmann J (2014) Motor outcome of dystonic camptocormia treated with pallidal neurostimulation. Parkinsonism Relat Disord 20:176–179
Segawa M (2011) Hereditary progressive dystonia with marked diurnal fluctuation. Brain Dev 33:195–201
Tinazzi M, Juergenson I, Squintani G, Vattemi G, Montemezzi S, Censi D, Barone P, Bovi T, Fasano A (2013) Pisa syndrome in Parkinson’s disease: an electrophysiological and imaging study. J Neurol 260:2138–2148
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Mensikova, K., Kaiserova, M., Vastik, M. et al. Treatment of camptocormia with continuous subcutaneous infusions of apomorphine: 1-year prospective pilot study. J Neural Transm 122, 835–839 (2015). https://doi.org/10.1007/s00702-014-1297-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00702-014-1297-9